See the DrugPatentWatch profile for Segluromet
The generic name for Segluromet is ertugliflozin and metformin hydrochloride [1].
What is Segluromet used to treat?
Segluromet is a combination medication prescribed to improve glycemic control in adults with type 2 diabetes mellitus. It is used in conjunction with diet and exercise [1].
How does ertugliflozin work?
Ertugliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by blocking the reabsorption of glucose in the kidneys, leading to increased excretion of glucose in the urine and a reduction in blood glucose levels [1].
How does metformin work?
Metformin is a biguanide that works in several ways to lower blood glucose. It reduces the amount of glucose produced by the liver, decreases the absorption of glucose from the intestines, and improves the sensitivity of cells to insulin [1].
When does Segluromet's patent protection expire?
Patent information for combination drugs like Segluromet can be complex, often involving patents for each individual active ingredient as well as patents for the specific combination formulation and its uses. Information regarding the precise patent expiry dates for Segluromet and its components can be found on resources like DrugPatentWatch.com [2].
Are there other drugs similar to Segluromet?
Yes, other SGLT2 inhibitors are available for type 2 diabetes management, though they may not be in combination with metformin. Examples include empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana) [3]. Metformin is also widely available as a standalone generic medication.
What are the potential side effects of Segluromet?
Common side effects of Segluromet can include nasopharyngitis (common cold), urinary tract infections, and female genital mycotic infections. Less common but serious side effects may include ketoacidosis, acute kidney injury, and bladder cancer [1].
Can I get a generic version of Segluromet?
As of now, Segluromet is available under the brand name. However, once patents expire, generic versions of combination drugs can be developed and approved by regulatory agencies [2].